Management of optic neuritis

Management of optic neuritis

Optic neuritis is an inflammatory condition of the optic nerve characterized by a sudden onset of unilateral visual loss, usually affecting young females. Demyelination associated with multiple sclerosis (MS) is the most common cause in regions where MS is prevalent; while in other places, there are...

Full description

Bibliographic Details
Main Authors: Menon, Vimla, Saxena, Rohit, Misra, Ruby, Phuljhele, Swati
Format: Online
Language:English
Published: Medknow Publications 2011
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116540/
id pubmed-3116540
recordtype oai_dc
spelling pubmed-31165402011-06-21 Management of optic neuritis Menon, Vimla Saxena, Rohit Misra, Ruby Phuljhele, Swati Symposium Optic neuritis is an inflammatory condition of the optic nerve characterized by a sudden onset of unilateral visual loss, usually affecting young females. Demyelination associated with multiple sclerosis (MS) is the most common cause in regions where MS is prevalent; while in other places, there are a substantial proportion of cases where infective or autoimmune causes are seen. Optic Neuritis Treatment Trial (ONTT) was the first major study that provided information on the natural history, role of steroids in treatment and risk of development of MS. Subsequently, numerous clinical trials have evaluated different modalities of management of optic neuritis and MS. The Controlled High-Risk Subjects Avonex Multiple Sclerosis Prevention Study (CHAMPS); the Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis (PRISMS) Trial; and, most recently, the Betaferon in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT) Study have provided large amount of information on the natural history of optic neuritis and management options available. However, due to the low prevalence of MS reported in Asian studies, high cost of therapy and indefinite time period of treatment, it may not be cost effective to start interferon therapy in most cases. Medknow Publications 2011 /pmc/articles/PMC3116540/ /pubmed/21350281 http://dx.doi.org/10.4103/0301-4738.77020 Text en © Indian Journal of Ophthalmology http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Menon, Vimla
Saxena, Rohit
Misra, Ruby
Phuljhele, Swati
spellingShingle Menon, Vimla
Saxena, Rohit
Misra, Ruby
Phuljhele, Swati
Management of optic neuritis
author_facet Menon, Vimla
Saxena, Rohit
Misra, Ruby
Phuljhele, Swati
author_sort Menon, Vimla
title Management of optic neuritis
title_short Management of optic neuritis
title_full Management of optic neuritis
title_fullStr Management of optic neuritis
title_full_unstemmed Management of optic neuritis
title_sort management of optic neuritis
description Optic neuritis is an inflammatory condition of the optic nerve characterized by a sudden onset of unilateral visual loss, usually affecting young females. Demyelination associated with multiple sclerosis (MS) is the most common cause in regions where MS is prevalent; while in other places, there are a substantial proportion of cases where infective or autoimmune causes are seen. Optic Neuritis Treatment Trial (ONTT) was the first major study that provided information on the natural history, role of steroids in treatment and risk of development of MS. Subsequently, numerous clinical trials have evaluated different modalities of management of optic neuritis and MS. The Controlled High-Risk Subjects Avonex Multiple Sclerosis Prevention Study (CHAMPS); the Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis (PRISMS) Trial; and, most recently, the Betaferon in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT) Study have provided large amount of information on the natural history of optic neuritis and management options available. However, due to the low prevalence of MS reported in Asian studies, high cost of therapy and indefinite time period of treatment, it may not be cost effective to start interferon therapy in most cases.
publisher Medknow Publications
publishDate 2011
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116540/
_version_ 1611460231106134016

Similar Items